Choi Suck Chei, Yun Ki Jung, Kim Tae Hyeon, Kim Hyun Ju, Park Seh Geun, Oh Gyung Jae, Chae Soo Cheon, Oh Gyung-Jae, Nah Yong Ho, Kim Jeong Joong, Chung Hun Tag
Department of Internal Medicine, Genomic Research Center for Immune Disorder, Institute of Wonkwang Medical Science, Wonkwang University School of Medicine, Iksan, Chonbuk 570-749, South Korea.
Cancer Lett. 2003 Jun 10;195(2):169-75. doi: 10.1016/s0304-3835(03)00158-7.
To improve understanding of glutathione S-transferase (GST) behavior in terms of a development and prognostic factor for gastric adenocarcinoma, we investigated the association between the GSTM1 and GSTT1 null genotypes and gastric cancer risk or the prognostic value of the GSTM1 and GSTT1 null genotypes was evaluated. Using a polymerase chain reaction-based method, the frequencies of GSTM1 and GSTT1 genotypes and prognostic factors, such as staging, differentiation, and histologic type (intestinal vs. diffuse), were evaluated in 80 patients with curatively resected primary gastric adenocarcinoma. The frequencies of GSTM1 and GSTT1 null individuals were higher in the gastric cancer group, but the differences were not statistically significant (for GSTM1 null odds ratio (OR)=0.86; 95% confidence interval (CI)=0.49-1.51 and for GSTT1, OR=0.97; 95% CI=0.55-1.71). Since the GSTM1 and GSTT1 null genotypes are potential indicators of gastric adenocarcinoma, we examined the relationship between the GSTM1 and GSTT1 genotypes and prognostic factors. In terms of the histologically diffuse type of cancer, GSTM1 indicated an approximately 3.24-fold increase (OR=3.24; 95% CI=1.05-10.17). With respect to gastric cancer differentiation, the frequency of the GSTM1 null genotype was linked with a statistically significant increase in risk (3.42-fold) for the high-grade type (OR=3.42; CI=1.02-13.24). Our results indicate that there is no obvious relationship between GSTM1 and GSTT1 polymorphisms and the development of gastric cancer. However, in Korean gastric adenocarcinoma patients the GSTM1 null genotype appears to be associated with a poorer prognosis.
为了更好地理解谷胱甘肽S-转移酶(GST)作为胃腺癌发生发展及预后因素的表现,我们研究了GSTM1和GSTT1基因缺失型与胃癌风险之间的关联,或评估了GSTM1和GSTT1基因缺失型的预后价值。采用基于聚合酶链反应的方法,对80例接受根治性切除的原发性胃腺癌患者的GSTM1和GSTT1基因型频率以及分期、分化程度和组织学类型(肠型与弥漫型)等预后因素进行了评估。胃癌组中GSTM1和GSTT1基因缺失个体的频率较高,但差异无统计学意义(GSTM1基因缺失的比值比(OR)=0.86;95%置信区间(CI)=0.49-1.51;GSTT1基因缺失的OR=0.97;95%CI=0.55-1.71)。由于GSTM1和GSTT1基因缺失型是胃腺癌的潜在指标,我们研究了GSTM1和GSTT1基因型与预后因素之间的关系。在组织学为弥漫型癌症方面,GSTM1显示风险增加约3.24倍(OR=3.24;95%CI=1.05-10.17)。关于胃癌分化,GSTM1基因缺失型的频率与高级别类型的风险显著增加(3.42倍)相关(OR=3.42;CI=1.02-13.24)。我们的结果表明,GSTM1和GSTT1基因多态性与胃癌的发生之间没有明显关系。然而,在韩国胃腺癌患者中,GSTM1基因缺失型似乎与较差的预后相关。